NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

pharmaphorum’s Managing Editor, Rebecca Aris, speaks with Gary Hendler of Eisai on Eisai’s current pipeline, what disease areas it will be focussing on and how its latest epilepsy drug ...

In a widely-anticipated study, Eisai and Biogen on Tuesday said their Alzheimer's drug slowed cognitive decline among people with early signs of the disease. The study, led by Eisai ...

CHICAGO, Sept 30 (Reuters) - Clear evidence this week that Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab drug lecanemab slows cognitive decline in early stage dementia has ...

The oncology and neurology pharmaceutical company from Japan announced rolling layoffs back in February impacting 57 employees at its headquarters in Nutley, according to a 2025 WARN notice. The ...

Eisai and Biogen said on Saturday the Japanese drugmaker had applied for full FDA approval of the drug. Sign up here. The drug, to be sold under the brand Leqembi, belongs to a class of treatments ...

Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This authorisation makes the amyloid-beta (Aβ ...

For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease that had confounded researchers for more than a century. To assess the ...